Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor
Jagdish Prasad(Pfizer (United States)), John W. Erickson(National Institutes of Health), Tod P. Holler(Pfizer (United States)), Bruce A. Steinbaugh(Pfizer (United States)), Sergei Gulnik(Beckman Coulter Foundation), Harriet W. Hamilton(Pfizer (United States)), A.G. Pavlovsky(Pfizer (United States)), Larry J. Markoski(Pfizer (United States)), Christopher Gajda(Pfizer (United States)), K. R. Krishna Iyer(University of Michigan), Susan E. Hagen(Pfizer (United States)), Elizabeth A. Lunney(Pfizer (United States)), Edmund L. Ellsworth(Pfizer (United States)), Peter J. Tummino(Ensemble Therapeutics (United States)), Christine Humblet(Pfizer (United States)), James M. Saunders(Pfizer (United States)), Carolyn Nouhan(Pfizer (United States)), Joanne Brodfuehrer(Pfizer (United States)), Neil M.H. Graham(UK Dementia Research Institute), Michael Sinz(Rutgers, The State University of New Jersey), A. Urumov(Pfizer (United States)), Donna Ferguson(Pfizer (United States)), Greg Zeikus(Pfizer (United States)), Donald Hupe(Pfizer (United States)), Steven VanderRoest(Pfizer (United States)), John R. Rubin(Pfizer (United States)), F Boyer(Pfizer (United States)), Bradley D. Tait(Pfizer (United States)), Stephen J. Gracheck(Pfizer (United States)), John M. Domagala(Pfizer (United States)), Eric Zeikus(Pfizer (United States))
Cited by 17
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|505
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis
|Gastroenterology|2019|448
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447